

Hamps Bio Ltd.

(Previously Known as Hamps Bio Pvt. Ltd.)

Date: November 14, 2025

To,
The Manager
BSE Limited
1st Floor, New Trading Ring,
Phiroze Jeejeebhoy Towers, Dalal Street, Fort,
Mumbai 400001 (Maharashtra)
Scrip Code: 544312

Subject: Outcome of the Board Meeting of HAMPS BIO LIMITED held on Friday, November 14, 2025, pursuant to the Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you, that the Board of Directors of the Company at its meeting held on today, Friday, November 14, 2025, at the corporate Office of the Company situated at Plot No C1 -B -106, Nr - Mama Bhanja Factory Bhatpore GIDC, Bhatpore, Surat, Choryasi, Gujarat, India, 394510, has inter-aila discussed and approved the following business:

1. Considered and approved the Unaudited Financial Results along with Limited review report for the half year ended 30.09.2025 and the same is attached herewith.

The Board Meeting commenced at 4:00 P.M (IST) and concluded at 6:00 P.M. (IST).

You are kindly requested to take the above on your record and update the same.

**Yours faithfully,
For HAMPS BIO LIMITED**

**MS. KOMAL JAIN
Company Secretary & Compliance Officer
Membership No.: ACS No. A40470**

Enclosure: As above

CIN No. : L24233GJ2007PLC049692

Factory : Unit - 1 : 2900/112, G.I.D.C. Industrial Estate, Nr. Atul Ltd., Ankleshwar - 393002

Unit - 2 : Plot No. C1-B-106, Nr- Mama Bhanja Factory, Bhatpore G.I.D.C., Surat, Gujarat, India 394510

E-mail : hamps.bio@gmail.com, Web : www.hampsbio.com, Mo.No. : 8000001113, 8000006663



MGHVS & ASSOCIATES
Chartered Accountants

☎ 8154912316, 9265096979
📞 7048388605, 9737211161

802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

Independent Auditors' Review Report on Standalone Unaudited Half Yearly Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors,
M/s. HAMPS BIO LIMITED

Opinion

We have reviewed the accompanying statement of Standalone Unaudited Financial results ("the statement") of **M/s. HAMPS BIO LIMITED** (the company) for the **Half year ended 30th September, 2025** being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors AND has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less





MGHVS & ASSOCIATES
Chartered Accountants

8154912316, 9265096979
7048388605, 9737211161

802-A, TRIVIDH CHAMBERS, OPP. MAAN DARWAJA FIRE STATION, RING ROAD, SURAT, GUJARAT-395002

assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our limited review, conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with Accounting Standard and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M G H V S & ASSOCIATES
Chartered Accountants



CA MUBASSIR M GODIL
(Partner)
M. No: 164503
FRN: 140555W
Place: Surat
Date: 14/11/2025
UDIN: 25164503BMHUHQ2082

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
(CIN: L24233GJ2007PLC049692)
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)
Balance Sheet as at 30th September 2025

Particulars	Note	30 September 2025	31 March 2025
I. EQUITY AND LIABILITIES			
(1) Shareholders' funds			
(a) Share Capital	1	871.20	435.60
(b) Reserves and Surplus	2	(20.55)	444.45
Total		850.65	880.05
(2) Non-current liabilities			
(a) Long-term Borrowings	3	246.10	202.67
(b) Other Long-term Liabilities	4	9.41	9.41
Total		255.51	212.08
(3) Current liabilities			
(a) Short-term Borrowings	5	127.51	94.06
(b) Trade Payables	6		
- Due to Micro and Small Enterprises		15.03	0.07
- Due to Others		42.09	60.17
(c) Other Current Liabilities	7	20.78	20.89
(d) Short-term Provisions	8	7.28	12.16
Total		212.69	187.35
Total Equity and Liabilities		1,318.85	1,279.48
II. ASSETS			
(1) Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets			
(i) Property, Plant and Equipment	9	391.29	248.18
(ii) Capital Work-in-progress	9	339.34	327.60
(iii) Intangible assets under development	9	-	10.80
(b) Non-current Investments	10	0.12	0.12
(c) Deferred Tax Assets (net)	11	6.85	7.04
(d) Other Non-current Assets	12	18.43	261.70
Total		756.03	855.44
(2) Current assets			
(a) Inventories	13	252.43	238.00
(b) Trade Receivables	14	99.61	119.22
(c) Cash and cash equivalents	15	104.36	9.57
(d) Short-term Loans and Advances	16	1.20	1.20
(e) Other Current Assets	17	105.22	56.06
Total		562.82	424.04
Total Assets		1,318.85	1,279.48

See accompanying notes to the financial statements
For and on behalf of the Board of Directors
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

FOR, HAMPS BIO LIMITED

HERRIK SHAH
MANAGING DIRECTOR
DIN : 01052316
Place: ANKLESHWAR
Date: 14/11/2025

FOR, HAMPS BIO LIMITED

WHOLE TIME DIRECTOR
DIN : 00973690

SHRENIK SHAH
WHOLE TIME DIRECTOR
00973690



HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
(CIN: L24233GJ2007PLC049692)
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)
Statement of Financial Results for the Half Year ended September 30, 2025

Particulars	6 Months ended		Year Ended	
	30/09/2025	31/03/2025	30/09/2024	31/03/2024
	Unaudited	Audited	Unaudited	Audited
Revenue from Operations	399.15	312.86	354.01	666.87
Other Income	3.80	6.70	8.41	15.11
Total Income	402.95	319.56	362.42	681.98
Expenses				
Cost of Material Consumed	32.17	49.39	35.84	85.24
Purchases of Stock in Trade	133.81	97.00	104.11	201.11
Change in Inventories of work in progress and finished goods	(9.63)	(60.78)	(25.65)	(86.43)
Employee Benefit Expenses	106.66	96.72	92.79	189.52
Finance Costs	11.33	5.94	8.01	13.95
Depreciation and Amortization Expenses	30.18	18.78	18.93	37.71
Other Expenses	117.79	108.27	92.24	200.51
Total expenses	422.31	315.33	376.27	641.60
Profit/(Loss) before Exceptional and Extraordinary Item and Tax	(19.36)	4.23	36.15	40.39
Exceptional Item	-	-	-	-
Profit/(Loss) before Extraordinary Item and Tax	(19.36)	4.23	36.15	40.39
Extraordinary Item	-	-	-	-
Profit/(Loss) before Tax	(19.36)	4.23	36.15	40.39
Tax Expenses				
- Current Tax	-	1.08	10.28	11.35
- Deferred Tax	0.20	(0.11)	(0.63)	(0.74)
Profit/(Loss) after Tax	(19.56)	3.27	26.50	29.77
Earnings Per Share (Face Value per Share Rs.10 each)				
- Basic (In Rs)	(0.22)	0.08	0.85	0.68
- Diluted (In Rs)	(0.22)	0.08	0.85	0.68

See accompanying notes to the financial statements

FOR, HAMPS BIO LIMITED

For and on behalf of the Board of Directors

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

MANAGING DIRECTOR
DIN : 01052316

HERRIK SHAH
MANAGING DIRECTOR
01052316
Place: ANKLESHWAR
Date: 14/11/2025

FOR, HAMPS BIO LIMITED

WHOLE TIME DIRECTOR
DIN : 00973690

SHRENIK SHAH
WHOLE TIME DIRECTOR
00973690

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
(CIN: L24233GJ2007PLC049692)
(Address: 2900/112, Near Atul Limited, G.I.D.C., Ankleshwar, Dist. Bharuch, Gujarat - 393002)
Cash Flow Statement for the Half year ended 30 September 2025

Particulars	30 September 2025	31 March 2025
CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit after tax	(19.36)	29.77
Profit/(loss) from Discontinuing Operation (after tax)	-	-
Depreciation and Amortisation Expense	30.18	37.71
Provision for tax	-	10.61
Other Adjustments	-	-
Dividend Income	-	-
Interest Income	(2.62)	(4.42)
Finance Costs	11.33	13.95
Operating Profit before working capital changes	19.53	87.62
Adjustment for:		
Inventories	(14.43)	(115.18)
Trade Receivables	19.61	(20.28)
Loans and Advances	-	11.23
Other Current Assets	(49.20)	(52.38)
Movement in deferred tax asset	-	(0.74)
Trade Payables	(3.12)	32.57
Other Current Liabilities	(0.10)	(0.10)
Long term Liabilities	-	-
Short-term Provisions	(4.88)	(4.67)
Long-term Provisions	-	2.08
Cash (Used in)/Generated from Operations	(32.59)	(59.85)
Tax paid(Net)	-	10.61
Net Cash (Used in)/Generated from Operating Activities	(32.59)	(70.47)
CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Property, Plant and Equipment	(174.23)	(371.92)
Proceeds from Sale / Redemption of Mutual Funds	-	-
Movement in other non current assets	243.28	(252.40)
Interest received	2.62	4.42
Dividend received	-	-
Net Cash (Used in)/Generated from Investing Activities	71.67	(619.89)
CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of Share Capital	-	622.20
Issue Expense	(9.84)	(106.36)
Buyback of Shares	-	-
Proceeds from Long Term Borrowings	70.00	184.94
Repayment of Long Term Borrowings	(26.57)	(11.83)
Proceeds from Short Term Borrowings	-	30.28
Repayment of Short Term Borrowings	33.45	(11.19)
Minority Interest Movement	-	-
Dividends Paid (including Dividend Distribution Tax)	-	-
Interest Paid	(11.33)	(13.95)
Net Cash (Used in)/Generated from Financing Activities	55.71	694.09
Net Increase/(Decrease) in Cash and Cash Equivalents	94.79	3.73
Opening Balance of Cash and Cash Equivalents	9.57	5.84
Exchange difference of Foreign Currency Cash and Cash equivalents	-	-
Closing Balance of Cash and Cash Equivalents	104.36	9.57

Note:

The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard 3 (AS-3), "Cash Flow Statements".

See accompanying notes to the financial statements

FOR, HAMPS BIO LIMITED
For and on behalf of the Board of Directors
HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

MANAGING DIRECTOR
DIN : 01052316

HERRIK SHAH
MANAGING DIRECTOR
01052316

FOR, HAMPS BIO LIMITED

WHOLE TIME DIRECTOR
DIN : 00973690

SHRENIK SHAH
WHOLE TIME DIRECTOR
00973690

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)
NOTES TO FINANCIAL RESULTS
CIN: L24233GJ2007PLC049692

1. The above financial results were reviewed by the audit committee and then approved by the board of directors in their meeting held on 14th November 2025
2. The results for the half year ended September 2025 are reviewed by the statutory auditor of the company in the compliance with the regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
3. These financial results prepared in accordance with the recognition and measurement principals of accounting standard (AS) prescribed under section 133 of the companies act 2013 read with the relevant rules issued there under and other accounting principles generally accepted in India.
4. The Earning Per Share (EPS) have been computed in accordance with Accounting Standard on Earning Per Share (EPS) AS-20
5. The comparative results for the half year ended 30th September 2024 have not been audited/reviewed by the statutory auditors of the company. The management has exercised due diligence to ensure that the said comparative results provide true & fair view.
6. The figures for the half year ended March 2025 are the balancing figures between the audited figures in respect of full financial year and the figures up to half year ended September 2024.
7. Based on guiding principles given in the Accounting standard on 'Segment Reporting' (AS-17), the business segment of the Company is trading of medicines (Pharma) and of manufacturing of Freeze dried products. The details of the same is as follows:

Year ended 30 th September, 2025	Pharma Products (Rs. in Lakhs)	Freeze dried Products (Rs. in Lakhs)	Total (Rs. in Lakhs)
Segment Revenue	189.20	209.95	399.15
Segment Assets	164.70	917.97	1082.67
Segment Liabilities	40.56	16.56	57.12

Note: Segment results are not reported, as it is not possible to compute segment net profit or loss, or any other measure of segment profitability, without arbitrary allocations.

The company is engaged in the manufacturing of freeze dried products and trading of pharmaceutical products. As a result, fixed assets are allocated to the freeze dried products segment and only details of debtors and stock are included in Pharma segment.

8. The previous year figures have been regrouped/reclassified wherever necessary to correspond with the current year classification for the comparison

9. The Company's inventory comprises Raw Materials, Finished Goods, and Stock-in-Trade. Inventories are valued at the lower of cost or net realizable value, in accordance with applicable accounting standards and the Company's accounting policy. The Management has derived the valuation of inventory based on FIFO method and includes all costs incurred in bringing the inventories to their present location and condition.
10. The Company has utilised proceeds from IPO as per the Object clause of the Prospectus as details below

Particulars	Total Estimated Cost (Rs in Lakhs)	Amount Utilised up to March 31st, 2025	Amount Utilised from April 25 to September 25
Purchase of Plant and Machinery & construction activity for FMCG division	359.00	111.00	100.15
Enhancing the visibility and awareness of the brand	50.00	14.00	15.88
General corporate purposes	151.87	151.87	-
Issue Expenses Paid	61.33	61.33	-
Total	622.20	338.20	116.03

During the year, the Company undertook expansion by way of purchase of Plant and Machinery and carried out construction activity pertaining to the FMCG division. The expenditure incurred includes components related to the acquisition of fixed assets, which have been capitalized in accordance with applicable accounting standards. Wages amounting to ₹36.07 lakh have been capitalised as they pertain to workers engaged in the construction of the factory premises.

The associated operating and running costs have been charged to the Statement of Profit and Loss as and when incurred.

Further, expenses incurred towards product development have been capitalized, being in the nature of capital expenditure, and are expected to generate future economic benefits.

For and on behalf of

HAMPS BIO LIMITED (Formerly Known as Hamps Bio Private Limited)

CIN: L24233GJ2007PLC049692

FOR, HAMPS BIO LIMITED

MANAGING DIRECTOR
DIN : 01052316

Herrik Shah
Managing Director
DIN : 01052316

FOR, HAMPS BIO LIMITED

WHOLE TIME DIRECTOR
DIN : 00973690

Shrenik Shah
Whole Time Director
DIN : 00973690

